| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MG1; MUC5; MUC9; MUC-5B |
| Entrez GeneID | 727897 |
| clone | 6F8B2 |
| WB Predicted band size | 596kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MUC5B (AA: 26-166) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MUC5B抗体的3-4篇参考文献及其摘要概括：
---
1. **文献名称**：*A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis*
**作者**：Seibold, M.A. et al.
**摘要**：该研究发现了MUC5B启动子的遗传多态性与特发性肺纤维化(IPF)风险的显著关联。通过免疫组织化学和分子分析，研究者使用MUC5B抗体证实了突变型启动子导致MUC5B蛋白在肺远端气道的异常高表达，提示其在IPF病理机制中的关键作用。
2. **文献名称**：*Production and Characterization of Monoclonal Antibodies to Human MUC5B Mucin*
**作者**：Thornton, D.J. et al.
**摘要**：研究团队开发并验证了针对MUC5B粘蛋白的单克隆抗体，通过免疫印迹和免疫组化技术证实其特异性。这些抗体成功区分了MUC5B与其他粘蛋白(如MUC5AC)，为后续研究MUC5B在正常组织及疾病中的分布提供了重要工具。
3. **文献名称**：*Abnormal Respiratory Mucin Expression in Idiopathic Pulmonary Fibrosis*
**作者**：Rose, M.C. et al.
**摘要**：该研究利用MUC5B抗体进行免疫染色，发现IPF患者肺组织中MUC5B在纤维化区域和肺泡空间的异常沉积，提示其可能通过黏液分泌失调促进疾病进展，为IPF的诊断和治疗提供了新靶点。
4. **文献名称**：*MUC5B and Mucosal Immunity: Insights into Innate Defense Mechanisms*
**作者**：Bingle, L. et al.
**摘要**：研究探讨了MUC5B在呼吸道先天免疫中的功能，通过抗体介导的定位实验揭示其在黏液屏障形成和病原体清除中的作用，强调了MUC5B抗体在解析黏膜防御机制中的重要性。
---
这些文献涵盖了MUC5B抗体的开发、应用及其在疾病机制研究中的关键作用，适用于实验方法参考或病理机制探讨。
The MUC5B antibody is a critical tool for studying the MUC5B mucin, a high-molecular-weight glycoprotein central to mucosal protection. MUC5B, a member of the gel-forming mucin family, is primarily secreted by submucosal glands in the respiratory tract, salivary glands, and the cervix. It plays a vital role in forming mucus hydrogels that trap pathogens, facilitate mucociliary clearance, and maintain tissue hydration. Structurally, MUC5B contains cysteine-rich domains enabling polymerization, tandem repeats with extensive O-glycosylation, and terminal regions mediating secretion.
Research using MUC5B antibodies has linked its dysregulation to diseases like idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Notably, a promoter polymorphism (rs35705950) in the MUC5B gene is strongly associated with IPF susceptibility, driving interest in its pathogenic role. Antibodies enable detection of MUC5B overexpression in IPF alveolar epithelia or its aberrant glycosylation in chronic inflammation.
In diagnostics, MUC5B antibodies aid in identifying mucus hypersecretion patterns or tumor-associated expression in adenocarcinomas. They also support mechanistic studies of mucus obstruction in airway diseases and evaluate therapeutic strategies targeting mucin production. Despite progress, challenges remain in distinguishing MUC5B from homologous mucins (e.g., MUC5AC) and interpreting context-specific glycosylation patterns. Ongoing work focuses on refining antibody specificity and exploring MUC5B's dual roles in protection versus pathology.
×
